FGFR3-TACC3 fusions also occur in other cancers, such as glioblastoma (3 out of 97 tumors examined, 3.1%), bladder cancer (2 of 43 bladder cancer cell lines, 4.7%) and nasopharyngeal carcinoma (4 out of 159 patients, 2.5%) [35–37]. Here, FGFR3 is linked to urinary bladder cancer.